Pharming Group (PHGUF) Stock Price, News & Analysis

Company Overview

Pharming Group NV is a Netherlands-based biopharmaceutical company specializing in the development and commercialization of protein replacement therapies for rare diseases. Founded in 1988 and headquartered in Leiden, the company leverages transgenic technology to produce recombinant proteins, with its flagship product RUCONEST (recombinant C1 esterase inhibitor) indicated for the treatment of acute hereditary angioedema (HAE) attacks. RUCONEST is approved and marketed in the United States, Europe and several other territories through partnerships with leading specialty pharmaceutical companies.

Beyond RUCONEST, Pharming maintains a diversified pipeline targeting unmet needs in rare and ultra-rare disorders. Lead pipeline candidates include odiparcil for mucopolysaccharidosis type VI and investigational therapies aimed at chronic inflammatory and complement-mediated conditions. The company conducts clinical trials across multiple regions and collaborates with partners such as Chiesi and other specialty pharma organizations to advance its programs through regulatory review, manufacturing scale-up and commercial launch preparations.

Pharming Group’s operations span North America, Europe and select markets in Asia and Latin America, reflecting its global commercialization footprint. The company’s leadership team is headed by CEO Roy van den Berg, supported by a management team with extensive experience in biotechnology R&D, global regulatory affairs and specialty-product marketing. Pharming Group is listed on Euronext Amsterdam (symbol PHARM) and trades in the United States on the OTC market under the symbol PHGUF.

Key Stats

• Today's Range: $1.30 to $1.30
• 50-Day Range: $1.15 to $1.30
• 52-Week Range: $1.14 to $2.17
• Volume: N/A
• Average Volume: N/A
• Market Capitalization: $872.39 million
• P/E Ratio: 108.33
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Last Earnings: 5/07/2026
• Today: 8/02/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: OTCMKTS:PHGUF
• Previous Symbol: OTC:PHGUF
• CIK: N/A
• Web: www.pharming.com
• Phone: (171) 524-7400
• Fax: 31-0-71-524-7445
• Employees: 382
• Year Founded: 1988

Profitability

• EPS (Trailing Twelve Months): $0.01
• Trailing P/E Ratio: 108.33
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $2.85 million
• Net Margins: 2.51%
• Pretax Margin: 5.38%
• Return on Equity: 3.40%
• Return on Assets: 1.88%

Debt

• Debt-to-Equity Ratio: 0.40
• Current Ratio: 2.63
• Quick Ratio: 2.06

Sales & Book Value

• Annual Sales: $376.13 million
• Price / Sales: 2.32
• Cash Flow: $0.02 per share
• Price / Cash Flow: 62.02
• Book Value: $0.41 per share
• Price / Book: 3.17

Miscellaneous

• Outstanding Shares: 671,070,000
• Free Float: N/A
• Market Cap: $872.39 million
• Optionable: Not Optionable
• Beta: 0.46